Form 4: Ensign Group Director Sells 700 Shares Under 10b5-1 Trading Plan

Barry M. Smith, a director at Ensign Group, Inc., sold 700 shares of common stock at $133.43 per share on January 2, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Barry M. Smith, a director of Ensign Group, Inc., executed a sale of 700 common stock shares on January 2, 2025.
• The sale was conducted at a price of $133.43 per share.
• This transaction was carried out under a pre-established Rule 10b5-1 trading plan adopted on July 31, 2024.
• Following the transaction, Mr. Smith directly owns 30,852 shares of Ensign Group common stock.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of a stock sale by a director under a pre-arranged plan, which is neither positive nor negative for the company's outlook.

Industry Context

This is a routine disclosure of a stock sale by a company director, which is common in the corporate world. The use of a 10b5-1 trading plan is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among corporate insiders to manage their stock sales, similar to practices at companies like UnitedHealth Group (UNH) and CVS Health (CVS).
• The transaction is a standard Form 4 filing, consistent with SEC regulations for reporting insider transactions, similar to filings made by directors at other publicly traded companies such as HCA Healthcare (HCA) and Tenet Healthcare (THC).

Stakeholder Impact

• The sale of shares by a director may have a minor impact on shareholder sentiment, but is unlikely to significantly affect the company's operations or financial health.

Key Dates

Keywords

Ensign Group, Director Sale, Form 4, 10b5-1 Trading Plan, Stock Transaction, Insider Trading